市場調査レポート

コンパニオン診断技術の世界市場(適応症・地域別) - 市場規模、シェア、世界動向、企業プロフィール、調査、レポート、機会、セグメンテーションおよび予測

Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

発行 Allied Market Research 商品コード 305984
出版日 ページ情報 英文 107 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
コンパニオン診断技術の世界市場(適応症・地域別) - 市場規模、シェア、世界動向、企業プロフィール、調査、レポート、機会、セグメンテーションおよび予測 Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日: 2014年06月14日 ページ情報: 英文 107 Pages
概要

コンパニオン診断は、特定の療法に対する患者固有の治療反応情報を事前に把握する新時代の体外診断技術であり、その市場は2013年時点での11億ドル規模を起点に以降20%の複合年間成長率を見せ、2020年には35億ドルに達するものと期待されます。

当レポートでは、コンパニオン診断の世界市場に注目し、今後の推移を適応症および地域の別に分析・予測するほか、発展の推進・抑制要因・機会、技術研究、用途開発、競合環境、主要参入企業などについての最新情報を集めています。

第1章 イントロダクション

  • レポート内容
  • 主要市場セグメント
  • 調査方法
    • 二次情報調査
    • 一次情報取材
    • 分析ツールおよびモデル

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 代謝疾患に対するコンパニオン診断
  • コンパニオン診断法の発展における新たな動向と技術
  • テーラーメイド医療の新たな潮流としてのコンパニオン診断
  • コンパニオン診断関連産業の基盤となるバイオマーカー市場
  • 重要所見
    • コンパニオン診断市場への主な影響要因
    • 成功への重要戦略
  • Poterのファイブフォース分析
  • 行政府規制
    • 米国食品医薬品局(FDA)規制
    • 欧州
    • 日本
    • 中国
  • バリューチェーン分析
  • 事例研究
  • 推進要因
    • テーラーメイド医療の人気上昇
    • 副作用(ADR)被害の頻発
    • バイオマーカー発見に伴う薬剤標的の増加
    • FDA承認迅速化による共同開発薬剤の成功拡大
    • 技術進歩
    • 疾患の多発化
  • 抑制要因
    • 高額な薬剤研究開発コスト
      • 経済的・科学的障害
  • 機会
    • 神経変性疾患治療の機会
    • 遺伝性突然変異に対するコンパニオン診断

第4章 コンパニオン診断の世界市場 - 適応症別

  • がん
  • 炎症・自己免疫疾患
  • 心血管疾患におけるコンパニオン診断
  • 中枢神経系障害におけるコンパニオン診断
  • ウイルス性疾患におけるコンパニオン診断検査
  • その他

第5章 コンパニオン診断の世界市場 - 技術別

  • コンパニオン診断技術市場 - 地域別
  • 免疫組織化学
  • 分子診断
  • プロテオミクス
  • トランスクリプトミクス(転写学)
  • メタボロミクス(代謝学)
  • 分子系統進化学
  • その他の用途市場
    • 薬理ゲノム学
    • 薬理プロテオミクス
    • バイオインフォマティクスのその他用途市場 - 地域別

第6章 コンパニオン診断の世界市場 - 地域別

  • 北米
  • 欧州
  • アジア太平洋州
  • その他の地域

第7章 企業プロフィール(企業概要、寸見、業績、戦略的動きおよび展開、SWOT分析)

  • Qiagen
  • Dako (Agilent Technologies)
  • Roche
  • Abbott Laboratories, Inc.
  • BioMerieux
  • Ventana Medical Systems
  • Myriad Genetics, Inc.
  • Resonance Health Ltd
  • Leica Microsystems
  • Life Technologies
目次
Product Code: DI 14135

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is the fastest growing region. The key drivers for this market are the increase in the discovery of biomarkers and co-development of drug and corresponding diagnostic. However, cost associated with developing drugs could impede the growth of this market. Opportunities for this market lie in developing companion diagnostics for various central nervous system conditions and hereditary conditions.

Companion Diagnostics Indication Market Analysis

Companion diagnostics is segmented on the basis of its use for indications such as oncology, cardiovascular conditions, central nervous system indications, inflammation and virology. Oncology is the highest revenue generating segment, as majority of the companion diagnostics have been developed for detection of various cancer biomarkers. The key driver for this market is an increase in research and development of targeted drugs, which require a corresponding companion diagnostic.

Companion Diagnostics Technology Market Analysis

Companion diagnostics technology market is segmented into Immunohistochemistry and Molecular diagnostics. Molecular diagnostics would be the fastest growing and highest revenue generator, mainly due to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing. Other factors contributing to the growth is technological advancements in molecular diagnostics, which has resulted in increased accuracy and precision and also reduced cost of testing using these methods.

Companion Diagnostics Geography Market Analysis

Companion Diagnostics market has been segmented geographically into North America, Europe, Asia Pacific and LAMEA. North America has the major market share of 43.97% followed by Europe, which accounted for about 38% of the overall CD market in 2013. North America and Europe together accounted for over 82% in the global CD market in 2013 and they would continue to be the major markets through 2020. This is mainly due to the increasing incidence of cancer and other diseases and higher health care awareness in these regions.

Competitive Analysis

A study of some of the key players has showed that majority of the companies in this market are focusing on collaborations with drug companies. Companion diagnostics is a emerging market and companies are collaborating with drug companies to develop companion diagnostics for their pipeline drugs, which are in developing phase. Approvals for companion diagnostics are the second most popular strategy. Companies profiled in this report include Dako (Agilent Technologies), Qiagen, Roche, Abbott Laboratories, Inc., Ventana Medical Systems, bioMerieux, Myriad Genetics, Inc., Resonance Health Ltd., Leica Microsystems, and Life Technologies.

High Level Analysis

The report is focusing on the trends in technology and diagnosis of various indications, which are driving the growth of the companion diagnostics market. Analysis of the market based on porters five force model shows that the bargaining power of the suppliers is high as the products produced are highly differentiated. The threat of new entrants is low as significant research and development is required for developing diagnostic tests. Apart from the R&D requirements, the investment required is also high. These factors make it difficult for new companies to enter the market. The threat of substitutes is low in this market as companion diagnostics are developed for specific biomarkers and the products are highly differentiated. Competition in this market is moderate as the market is still emerging and there are a few companies in the market. Government regulations are favoring use of companion diagnostics for determining a particular treatment. Companies are focusing on collaborations with pharmaceutical companies as a key strategy to gain competitive advantage.

Reason for doing the study

Companion diagnostics are an important aspect of the personalized treatment approach and are essential for predicting the therapeutic response to a particular drug. With increasing awareness among the population and rising incidences of cancer, companion diagnostics would become an essential factor for targeted therapeutic approach. More and more companies are developing targeted therapeutics products and companion diagnostics is an integral part of their strategy.

KEY BENEFITS

  • In-depth analysis of the companion diagnostic market by technology and indications give a clear idea of the scope of this market
  • Analysis of the market by geography would help in making region specific plans
  • Estimations for period of 2013 to 2020 have been given, taking into consideration the current market scenario and future trends, which would give a clearer picture of the potential of the market
  • Porter's five force model and SWOT analysis would help in a deeper understanding of the market and help in making strategic decisions
  • Top factors impacting the market would help in making decisions for business development

KEY DELIVERABLES

MARKET BY INDICATIONS

  • Oncology
  • Cardiovascular
  • Central Nervous System
  • Auto immune & Inflammation
  • Virology
  • Others

MARKET BY TECHNOLOGY

  • Immunohistochemistry
  • Molecular diagnostics
  • In situ Hybridization
  • FISH
  • CISH
  • Real time PCR
  • Gene Sequencing

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Research methodology
    • 1.3.1. Secondary research
    • 1.3.2. Primary research
    • 1.3.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Companion Diagnostics for Metabolic Diseases
  • 3.3. Novel trends and technologies in companion diagnostics assay development
  • 3.4. Companion diagnostics as a new trend in personalized medicine
  • 3.5. Biomarkers market as basis for the companion diagnostics industry
  • 3.6. Key Findings
    • 3.6.1. Top Factors Impacting The Companion Diagnostic Market
    • 3.6.2. Top Winning Strategies
  • 3.7. Porter's five forces analysis
    • 3.7.1. High switching cost leads to higher bargaining power of suppliers
    • 3.7.2. Highly differentiated products leads to lower bargaining power of buyers
    • 3.7.3. Specificity of diagnostics lowers the threat of substitutes
    • 3.7.4. Higher capital investment leads to lesser threat of entrants
    • 3.7.5. Few competitors leads to low competition among players
  • 3.8. Government Regulations
    • 3.8.1. FDA regulations
    • 3.8.2. Europe
    • 3.8.3. Japan
    • 3.8.4. China
  • 3.9. Value Chain Analysis
  • 3.10. Case Study
  • 3.11. Drivers
    • 3.11.1. Increased popularity of Personalized medicine
    • 3.11.2. Increasing cases of adverse drug reactions(ADRs)
    • 3.11.3. Increase in the Discovery of Biomarkers as drug targets.
    • 3.11.4. Rising success of co-development drugs speedily approved by the FDA
    • 3.11.5. Technological advancements
    • 3.11.6. Rising incidences of diseases
  • 3.12. Restraints
    • 3.12.1. High Cost in research and development of drugs
      • 3.12.1.1. Economic and scientific obstacles
    • 3.12.2. Opportunities
      • 3.12.2.1. Opportunities in treatment of neurodegenerative diseases
      • 3.12.2.2. Companion diagnostics for hereditary mutations

CHAPTER 4 - GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATIONS

  • 4.1. Oncology
    • 4.1.1. Companion diagnostics oncology market by geography,
    • 4.1.2. Breast Cancer
      • 4.1.2.1. companion diagnostics breast cancer market by geography
    • 4.1.3. Lung Cancer
      • 4.1.3.1. companion diagnostics lung cancer market by geography
    • 4.1.4. Colorectal Cancer
      • 4.1.4.1. companion diagnostics Colorectal Cancer market by geography
    • 4.1.5. Gastric cancer
      • 4.1.5.1. companion diagnostics Gastric Cancer market by geography
    • 4.1.6. Melanomas
      • 4.1.6.1. companion diagnostics Melanoma market by geography
  • 4.2. Inflammation and Autoimmune diseases
    • 4.2.1. Companion diagnostics inflammation market by geography
  • 4.3. Companion diagnostics in cardiovascular diseases
    • 4.3.1. Companion diagnostics tests for warfarin
    • 4.3.2. Companion diagnostics cardiovascular market by geography
  • 4.4. Companion diagnostics in CNS disorders
    • 4.4.1. Companion diagnostics CNS market by geography
  • 4.5. Companion diagnostics tests in virology diseases
    • 4.5.1. Companion diagnostics virology market by geography
  • 4.6. Others
    • 4.6.1. Companion diagnostics others market by geography

CHAPTER 5 - GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY

  • 5.1. Companion diagnostics technology market by geography
  • 5.2. Immunohistochemistry
    • 5.2.1. Companion diagnostics Immmunohistochemistry market by geography
  • 5.3. Molecular Diagnostics
    • 5.3.1. Companion diagnostics molecular diagnostics market by types
    • 5.3.2. Companion diagnostics Molecular Diagnostics market by geography
    • 5.3.3. In-situ Hybridization
      • 5.3.3.1. Fluorescent In-situ Hybridization(FISH)
      • 5.3.3.2. CISH (Chromogenic In-Situ Hybridization)
      • 5.3.3.3. Companion diagnostics In situ Hybridization market by geography
    • 5.3.4. Real Time PCR
      • 5.3.4.1. Companion diagnostics RT PCR market by geography
    • 5.3.5. Gene Sequencing
      • 5.3.5.1. Companion diagnostics Sequencing market by geography
    • 5.3.6. Others
      • 5.3.6.1. Others molecular companion diagnostics market by geography

CHAPTER 6 - GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. Companion diagnostics North America market by indication
  • 6.2. Europe
    • 6.2.1. Companion diagnostics Europe market by indication
  • 6.3. Asia Pacific
    • 6.3.1. Companion diagnostics Asia Pacific market by indication
  • 6.4. RoW
    • 6.4.1. Companion diagnostics RoW market by indication

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Qiagen
    • 7.1.1. Company Overview:
    • 7.1.2. Company Snapshot
    • 7.1.3. Business Performance
    • 7.1.4. Strategy move and development
      • 7.1.4.1. Principal strategies Collaborations
      • 7.1.4.2. Secondary Strategies Approval
    • 7.1.5. SWOT Analysis of Qiagen
  • 7.2. Dako (Agilent Technologies)
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Business Performance
    • 7.2.4. Strategic Moves and Development
      • 7.2.4.1. Principal strategies Collaboration
      • 7.2.4.2. Secondary Strategies Approval
    • 7.2.5. SWOT Analysis of Dako
  • 7.3. Roche
    • 7.3.1. Company overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Business Performance
    • 7.3.4. Strategies move and development
    • 7.3.5. SWOT analysis of Roche
  • 7.4. Abbott Laboratories, Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Business Performance
    • 7.4.4. Principal Strategies Collaboration
    • 7.4.5. SWOT Analysis of Abbot
  • 7.5. BioMerieux
    • 7.5.1. Company Overview
    • 7.5.2. Company snapshot:
    • 7.5.3. Business Performance
    • 7.5.4. Strategies and development Approval
    • 7.5.5. SWOT Analysis of BioMerieux,
  • 7.6. Ventana Medical Systems
    • 7.6.1. Company Profile
    • 7.6.2. Company Snapshot
    • 7.6.3. Business Performance
    • 7.6.4. Strategies and development
    • 7.6.5. SWOT Analysis of Ventana
  • 7.7. Myriad Genetics, Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company snapshot
    • 7.7.3. Business Performance
    • 7.7.4. Strategies and development
    • 7.7.5. SWOT Analysis of Myraid
  • 7.8. Resonance Health Ltd
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Strategies move and development
    • 7.8.4. SWOT Analysis of Ferriscan
  • 7.9. Leica Microsystems
    • 7.9.1. Company overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Strategies move and Development
    • 7.9.4. SWOT Analysis of Leica Microsystems
  • 7.10. Life Technologies
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Business performance
    • 7.10.4. Strategies move and Development
    • 7.10.5. SWOT Analysis of Life Technologies

LIST OF TABLES:

  • TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2013-2020 ($MILLION)
  • TABLE 2: COMPANION DIAGNOSTICS INDICATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET BY ONCOLOGY, 2013-2020, ($MILLION)
  • TABLE 4: COMPANION DIAGNOSTICS ONCOLOGY MARKET BY GEOGRAPHY, 2013-2020, ($MILLION)
  • TABLE 5: COMPANION DIAGNOSTICS BREAST CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 6: COMPANION DIAGNOSTICS LUNG CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 7: COMPANION DIAGNOSTICS COLORECTAL CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 8: COMPANION DIAGNOSTICS GASTRIC CANCER MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 9: COMPANION DIAGNOSTICS MELANOMA MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 10: COMPANION DIAGNOSTICS INFLAMMATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 11: COMPANION DIAGNOSTICS CARDIOVASCULAR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 12: COMPANION DIAGNOSTICS CNS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 13: COMPANION DIAGNOSTICS VIROLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 14: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 15: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY TECHNOLOGY 2013-2020 ($MILLION)
  • TABLE 16: COMPANION DIAGNOSTICS TECHNOLOGY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 17: COMPANION DIAGNOSTICS IMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 18: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY TYPES 2013-2020 ($MILLION)
  • TABLE 19: COMPANION DIAGNOSTICS MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 20: COMPANION DIAGNOSTICS IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 21: COMPANION DIAGNOSTICS RT PCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 22: COMPANION DIAGNOSTICS SEQUENCING MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 23: OTHERS MOLECULAR COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 24: COMPANION DIAGNOSTICS OTHERS MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
  • TABLE 25: COMPANION DIAGNOSTICS NORTH AMERICA MARKET, 2013-2020 ($MILLION)
  • TABLE 26: COMPANION DIAGNOSTICS EUROPE MARKET, 2013-2020 ($MILLION)
  • TABLE 27: COMPANION DIAGNOSTICS ASIA-PACIFIC MARKET, 2013-2020 ($MILLION)
  • TABLE 28: COMPANION DIAGNOSTICS ROW MARKET, 2013-2020 ($MILLION)
  • TABLE 29: QIAGEN SNAPSHOT
  • TABLE 30: DAKO COMPANY SNAPSHOT
  • TABLE 31: ROCHE COMPANY SNAPSHOT
  • TABLE 32: ABBOTT COMPANY SNAPSHOT
  • TABLE 33: BIOMERIEUX COMPANY SNAPSHOT
  • TABLE 34: VENTANA COMPANY SNAPSHOT
  • TABLE 35: MYRIAD COMPANY SNAPSHOT
  • TABLE 36: RESONANCE COMPANY SNAPSHOT
  • TABLE 37: LEICA COMPANY SNAPSHOT
  • TABLE 38: LIFE TECHNOLOGIES COMPANY SNAPSHOT

LIST OF FIGURES:

  • FIG.1: OMPANION DIAGNOSTICS AS A NEW TREND IN PERSONALIZED MEDICINE
  • FIG.2: FFECTIVENESS OF COMPANION DIAGNOSTICS IN LUNG CANCER PATIENTS
  • FIG.3: IST BIOMARKERS AND THE COMPANION DIAGNOSTICS FOR VARIOUS DISEASES
  • FIG.4: OP FACTORS IMPACTING THE COMPANION DIAGNOSTIC MARKET
  • FIG.5: OP WINNING STRATEGIES
  • FIG.6: ALUE CHAIN ANALYSIS
  • FIG.7: INANCIAL REVENUES BY BUSINESS UNITS (2013)
  • FIG.8: INANCIAL REVENUES BY GEOGRAPHY(2013)
  • FIG.9: WOT ANALYSIS OF QIAGEN
  • FIG.10: INANCIAL REVENUE OF DAKO, BY SEGMENT (2012)
  • FIG.11: WOT ANALYSIS OF DAKO
  • FIG.12: INANCIAL REVENUE OF DAKO, BY SEGMENT
  • FIG.13: INANCIAL REVENUE OF DAKO, BY GEOGRAPHY
  • FIG.14: WOT ANALYSIS OF ROCHE
  • FIG.15: EVENUE BY BUSINESS SEGMENTS
  • FIG.16: EVENUE BY GEOGRAPHY
  • FIG.17: WOT ANALYSIS OF ABBOTT
  • FIG.18: INANCIAL REVENUES BY GEOGRAPHY
  • FIG.19: INANCIAL REVENUES BY TECHNOLOGY
  • FIG.20: WOT ANALYSIS OF BIOMERIEUX
  • FIG.21: WOT ANALYSIS OF VENTANA
  • FIG.22: EVENUE BY DIAGNOSTIC TYPE
  • FIG.23: WOT ANALYSIS OF MYRAID
  • FIG.24: WOT ANALYSIS OF FERRISCAN
  • FIG.25: WOT ANALYSIS OF LEICA MICROSYSTEMS
  • FIG.26: EVENUE BY END MARKETS
  • FIG.27: WOT ANALYSIS OF LIFE TECHNOLOGIES
Back to Top